PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
These abstracts report on the company's three lead drug candidates, including olverembatinib
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Subscribe To Our Newsletter & Stay Updated
